These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

221 related items for PubMed ID: 22922573

  • 1. The synergistic effects of low-dose irinotecan and TRAIL on TRAIL-resistant HT-29 colon carcinoma in vitro and in vivo.
    Zhu H, Zhao F, Yu S, He J, Deng L, Yi C, Huang Y.
    Int J Mol Med; 2012 Nov; 30(5):1087-94. PubMed ID: 22922573
    [Abstract] [Full Text] [Related]

  • 2. Apoptosis induction in prostate cancer cells and xenografts by combined treatment with Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand and CPT-11.
    Ray S, Almasan A.
    Cancer Res; 2003 Aug 01; 63(15):4713-23. PubMed ID: 12907654
    [Abstract] [Full Text] [Related]

  • 3. Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with chemotherapeutic agents on patients' colon tumors grown in SCID mice.
    Naka T, Sugamura K, Hylander BL, Widmer MB, Rustum YM, Repasky EA.
    Cancer Res; 2002 Oct 15; 62(20):5800-6. PubMed ID: 12384541
    [Abstract] [Full Text] [Related]

  • 4. Treatment of human colon cancer xenografts with TRA-8 anti-death receptor 5 antibody alone or in combination with CPT-11.
    Oliver PG, LoBuglio AF, Zinn KR, Kim H, Nan L, Zhou T, Wang W, Buchsbaum DJ.
    Clin Cancer Res; 2008 Apr 01; 14(7):2180-9. PubMed ID: 18381960
    [Abstract] [Full Text] [Related]

  • 5. Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo.
    Singh TR, Shankar S, Chen X, Asim M, Srivastava RK.
    Cancer Res; 2003 Sep 01; 63(17):5390-400. PubMed ID: 14500373
    [Abstract] [Full Text] [Related]

  • 6. Delivery of tumor-homing TRAIL sensitizer with long-acting TRAIL as a therapy for TRAIL-resistant tumors.
    Oh Y, Swierczewska M, Kim TH, Lim SM, Eom HN, Park JH, Na DH, Kim K, Lee KC, Pomper MG, Lee S.
    J Control Release; 2015 Dec 28; 220(Pt B):671-81. PubMed ID: 26381901
    [Abstract] [Full Text] [Related]

  • 7. Requirement of p53 targets in chemosensitization of colonic carcinoma to death ligand therapy.
    Wang S, El-Deiry WS.
    Proc Natl Acad Sci U S A; 2003 Dec 09; 100(25):15095-100. PubMed ID: 14645705
    [Abstract] [Full Text] [Related]

  • 8. Tumor necrosis factor-related apoptosis-inducing ligand's antitumor activity in vivo is enhanced by the chemotherapeutic agent CPT-11.
    Gliniak B, Le T.
    Cancer Res; 1999 Dec 15; 59(24):6153-8. PubMed ID: 10626806
    [Abstract] [Full Text] [Related]

  • 9. Elimination of hepatic metastases of colon cancer cells via p53-independent cross-talk between irinotecan and Apo2 ligand/TRAIL.
    Ravi R, Jain AJ, Schulick RD, Pham V, Prouser TS, Allen H, Mayer EG, Yu H, Pardoll DM, Ashkenazi A, Bedi A.
    Cancer Res; 2004 Dec 15; 64(24):9105-14. PubMed ID: 15604280
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. 2-methoxy-5-amino-N-hydroxybenzamide sensitizes colon cancer cells to TRAIL-induced apoptosis by regulating death receptor 5 and survivin expression.
    Stolfi C, Caruso R, Franzè E, Rizzo A, Rotondi A, Monteleone I, Fantini MC, Pallone F, Monteleone G.
    Mol Cancer Ther; 2011 Oct 15; 10(10):1969-81. PubMed ID: 21817114
    [Abstract] [Full Text] [Related]

  • 12. Evaluation of preventive and therapeutic activity of novel non-steroidal anti-inflammatory drug, CG100649, in colon cancer: Increased expression of TNF-related apoptosis-inducing ligand receptors enhance the apoptotic response to combination treatment with TRAIL.
    Woo JK, Kang JH, Jang YS, Ro S, Cho JM, Kim HM, Lee SJ, Oh SH.
    Oncol Rep; 2015 Apr 15; 33(4):1947-55. PubMed ID: 25672292
    [Abstract] [Full Text] [Related]

  • 13. Phytosphingosine in combination with TRAIL sensitizes cancer cells to TRAIL through synergistic up-regulation of DR4 and DR5.
    Choi SY, Kim MJ, Chung HY, Lee SJ, Jang YJ.
    Oncol Rep; 2007 Jan 15; 17(1):175-84. PubMed ID: 17143496
    [Abstract] [Full Text] [Related]

  • 14. Low-dose 5-fluorouracil sensitizes HepG2 cells to TRAIL through TRAIL receptor DR5 and survivin-dependent mechanisms.
    Yang L, Wang Y, Zheng H, Zhang D, Wu X, Sun G, Yang T.
    J Chemother; 2017 Jun 15; 29(3):179-188. PubMed ID: 28067150
    [Abstract] [Full Text] [Related]

  • 15. Tunicamycin enhances human colon cancer cells to TRAIL-induced apoptosis by JNK-CHOP-mediated DR5 upregulation and the inhibition of the EGFR pathway.
    Guo X, Meng Y, Sheng X, Guan Y, Zhang F, Han Z, Kang Y, Tai G, Zhou Y, Cheng H.
    Anticancer Drugs; 2017 Jan 15; 28(1):66-74. PubMed ID: 27603596
    [Abstract] [Full Text] [Related]

  • 16. The histone deacetylase inhibitor PXD101 increases the efficacy of irinotecan in in vitro and in vivo colon cancer models.
    Na YS, Jung KA, Kim SM, Hong YS, Ryu MH, Jang SJ, Moon DH, Cho DH, Kim JC, Lee JS, Kim TW.
    Cancer Chemother Pharmacol; 2011 Aug 15; 68(2):389-98. PubMed ID: 21046105
    [Abstract] [Full Text] [Related]

  • 17. Enhanced tumor killing by Apo2L/TRAIL and CPT-11 co-treatment is associated with p21 cleavage and differential regulation of Apo2L/TRAIL ligand and its receptors.
    Xiang H, Fox JA, Totpal K, Aikawa M, Dupree K, Sinicropi D, Lowe J, Escandón E.
    Oncogene; 2002 May 16; 21(22):3611-9. PubMed ID: 12032863
    [Abstract] [Full Text] [Related]

  • 18. BAY61-3606 potentiates the anti-tumor effects of TRAIL against colon cancer through up-regulating DR4 and down-regulating NF-κB.
    Du J, Wang Y, Chen D, Ji G, Ma Q, Liao S, Zheng Y, Zhang J, Hou Y.
    Cancer Lett; 2016 Dec 28; 383(2):145-153. PubMed ID: 27721019
    [Abstract] [Full Text] [Related]

  • 19. The flavonolignan silibinin potentiates TRAIL-induced apoptosis in human colon adenocarcinoma and in derived TRAIL-resistant metastatic cells.
    Kauntz H, Bousserouel S, Gossé F, Raul F.
    Apoptosis; 2012 Aug 28; 17(8):797-809. PubMed ID: 22555452
    [Abstract] [Full Text] [Related]

  • 20. Prediction of proapoptotic anticancer therapeutic response in vivo based on cell death visualization and TRAIL death ligand-receptor interaction.
    Zhou L, Wang W, Dicker DT, Humphreys RC, El-Deiry WS.
    Cancer Biol Ther; 2011 Aug 15; 12(4):335-48. PubMed ID: 21785270
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.